https://prabadinews.com/
  • October 8, 2026
  • Last Update July 17, 2026 9:28 pm
  • United States of America

Drug Trials Snapshot: VANRAFIA

Drug Trials Snapshot: VANRAFIA

VANRAFIA is an endothelin type A receptor antagonist that is indicated to reduce proteinuria in adults with primary immunoglobulin A (IgA) nephropathy at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) ≥1.5 g/g. Learn more about the clinical trials.

administrator

Related Articles